There are upsides and downsides to this arrangement.
The upside for IVX shareholders, is less dilution. RMW Cho Group is funding the cancer research. So obviously they would want the biggest piece of the pie. I am sure IMU holders on this forum will remember the number of times they had to raise capital to fund research.
Of course, the downside is - for cancer treatments at least, is our arrangement limit us to Australia and NZ.
However, we should remember, this Technology is NOT limited to cancer treatments.
There are still "atherosclerosis and infectious diseases" which we hold the Asia Pacific licence (excluding greater China).
IVX Price at posting:
3.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)